JP2020530447A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020530447A5 JP2020530447A5 JP2020505881A JP2020505881A JP2020530447A5 JP 2020530447 A5 JP2020530447 A5 JP 2020530447A5 JP 2020505881 A JP2020505881 A JP 2020505881A JP 2020505881 A JP2020505881 A JP 2020505881A JP 2020530447 A5 JP2020530447 A5 JP 2020530447A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- compound
- individual
- solvate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 29
- 229940125904 compound 1 Drugs 0.000 claims 13
- 150000003839 salts Chemical class 0.000 claims 11
- 239000012453 solvate Substances 0.000 claims 11
- 206010010904 Convulsion Diseases 0.000 claims 4
- 208000012322 Raynaud phenomenon Diseases 0.000 claims 4
- 201000009594 Systemic Scleroderma Diseases 0.000 claims 4
- 206010042953 Systemic sclerosis Diseases 0.000 claims 4
- 208000025865 Ulcer Diseases 0.000 claims 4
- 230000002265 prevention Effects 0.000 claims 4
- 231100000397 ulcer Toxicity 0.000 claims 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 3
- 238000011282 treatment Methods 0.000 claims 3
- 208000003782 Raynaud disease Diseases 0.000 claims 2
- 230000000302 ischemic effect Effects 0.000 claims 2
- 230000000451 tissue damage Effects 0.000 claims 2
- 231100000827 tissue damage Toxicity 0.000 claims 2
- 238000004448 titration Methods 0.000 claims 2
- -1 (4-chlorophenyl) (phenyl) carbamoyloxy Chemical group 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 206010017711 Gangrene Diseases 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 201000003278 cryoglobulinemia Diseases 0.000 claims 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 208000003532 hypothyroidism Diseases 0.000 claims 1
- 230000002989 hypothyroidism Effects 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762541956P | 2017-08-07 | 2017-08-07 | |
| US62/541,956 | 2017-08-07 | ||
| US201862711369P | 2018-07-27 | 2018-07-27 | |
| US62/711,369 | 2018-07-27 | ||
| PCT/US2018/045683 WO2019032626A1 (en) | 2017-08-07 | 2018-08-07 | Methods of treatment |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020530447A JP2020530447A (ja) | 2020-10-22 |
| JP2020530447A5 true JP2020530447A5 (enExample) | 2021-09-16 |
| JP7343478B2 JP7343478B2 (ja) | 2023-09-12 |
Family
ID=63364217
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020505881A Active JP7343478B2 (ja) | 2017-08-07 | 2018-08-07 | 処置の方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US20200368190A1 (enExample) |
| EP (1) | EP3664792A1 (enExample) |
| JP (1) | JP7343478B2 (enExample) |
| CA (1) | CA3072079A1 (enExample) |
| WO (1) | WO2019032626A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2367797A1 (en) | 2008-11-26 | 2011-09-28 | Arena Pharmaceuticals, Inc. | Pyrazolyl substituted carbonic acid derivatives as modulators of the prostacyclin (pgi2) receptor useful for the treatment of disorders related thereto |
| PT2370413E (pt) | 2008-12-08 | 2015-10-23 | Arena Pharm Inc | Moduladores do recetor da prostaciclina (pgi2) úteis para o tratamento de distúrbios relacionados com o mesmo |
| WO2023158634A1 (en) | 2022-02-15 | 2023-08-24 | United Therapeutics Corporation | Crystalline prostacyclin (ip) receptor agonist and uses thereof |
| US20250282716A1 (en) | 2024-03-11 | 2025-09-11 | United Therapeutics Corporation | Methods of making ip-receptor agonists |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8895776B2 (en) * | 2008-03-18 | 2014-11-25 | Arena Pharmaceuticals, Inc. | Modulators of the prostacyclin (PGI2) receptor useful for the treatment of disorders related thereto |
| ES2762943T3 (es) * | 2015-09-03 | 2020-05-26 | Teva Pharmaceuticals Int Gmbh | Formas de Selexipag en estado sólido |
-
2018
- 2018-08-07 EP EP18759520.2A patent/EP3664792A1/en active Pending
- 2018-08-07 CA CA3072079A patent/CA3072079A1/en active Pending
- 2018-08-07 US US16/636,608 patent/US20200368190A1/en not_active Abandoned
- 2018-08-07 JP JP2020505881A patent/JP7343478B2/ja active Active
- 2018-08-07 WO PCT/US2018/045683 patent/WO2019032626A1/en not_active Ceased
-
2023
- 2023-06-14 US US18/335,052 patent/US20240122886A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023503309A5 (enExample) | ||
| FI3562486T3 (fi) | Kielenalaisen deksmedetomidiinin käyttö agitaation hoidossa | |
| RU2016144479A (ru) | Фармацевтические композиции для лечения заболеваний, опосредопосредованных муковисцидозным трансмембранным регулятором проводимости | |
| IL314009B1 (en) | Parp1 inhibitors and uses thereof | |
| JP2018021046A5 (enExample) | ||
| JP2020193206A5 (enExample) | ||
| JP2018534348A5 (enExample) | ||
| CN101031305A (zh) | 类风湿性关节炎的预防和/或治疗药物 | |
| JP2015522630A5 (enExample) | ||
| JP2020529995A5 (enExample) | ||
| JP2020523335A5 (enExample) | ||
| RU2019100037A (ru) | Способ лечения рассеянного склероза с использованием ингибитора lsd1 | |
| RU2017116740A (ru) | Комбинации для лечения рассеянного склероза | |
| WO2008142572A3 (en) | Controlled release tablet formulation containing magnesium aluminometasilicate | |
| AU2015205188A1 (en) | Pharmaceutical preparation containing pyridylamino acetic acid compound | |
| JP2017514911A5 (enExample) | ||
| HRP20241716T1 (hr) | Postupci liječenja promjena u ponašanju | |
| ME02474B (me) | Terapijski režimi | |
| JP2022534510A5 (enExample) | ||
| HRP20251043T1 (hr) | Novi oralni farmaceutski pripravak i režim doziranja za terapiju progresivnih fibrozirajućih intersticijskih bolesti pluća | |
| JP2004505036A5 (enExample) | ||
| JP2015531749A5 (enExample) | ||
| JP2018505218A5 (enExample) | ||
| ES2390226T3 (es) | Tratamiento de enfermedades infecciosas | |
| JP2016505050A5 (enExample) |